Azadyne

Azadyne is a pharma R&D company based in the United Kingdom that focuses on developing improved medicines for patients with autoimmune diseases, primarily Multiple Sclerosis. The company's roots can be traced back to the research conducted by Profs Vincent P. Kelly, Stephen Connon, and J. Mike Southern at Trinity Biomedical Sciences Institute, Trinity College Dublin. Autoimmune diseases, which include conditions such as Multiple Sclerosis, Rheumatoid Arthritis, and Inflammatory Bowel Disease, are chronic and currently incurable conditions resulting from the body mistakenly attacking itself, leading to inflammation and damage. Azadyne's innovative approach revolves around harnessing the potential of a naturally occurring micronutrient called queuine to control the autoimmune response in the body. The company has made significant strides in the development of new molecules that promise improved therapeutic outcomes for patients and their families. Azadyne's candidates are progressing towards Phase I or FIH trials, showcasing their commitment to bringing practical solutions to the market. Having been founded in 2016, Azadyne secured a Venture Round investment on 03 September 2020, with Renaissance Capital Partners as the supporting investors. Their dedication to addressing unmet medical needs in the field of autoimmune diseases positions Azadyne as a promising venture in the Health Care industry, with the potential to make a significant impact in the pharmaceutical landscape.